Currently, there are no established treatments for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection that causes coronavirus infectious disease 2019 (COVID-19). However, remdesivir was recently granted Emergency Use Authorization for treatment of severe disease by the US Food and Drug Administration (FDA) pending completion of ongoing studies. In addition, a number of repurposed drugs, as well as novel agents, are under investigation (see https://clinicaltrials.gov/ct2/results?cond=COVID-19).

**SARS-COV-2 VIRUS**

SARS-CoV-2 is a single-stranded, enveloped RNA virus that shares 80% genome homology with the severe acute respiratory syndrome (SARS; CoV-1) virus. The majority of deaths from COVID-19 are due to severe pneumonia with multiorgan failure that develops more frequently in the elderly and those with medical comorbidities.¹ SARS-CoV-2, like other coronaviruses, infects the epithelium of the nasopharynx and lung, and is highly transmissible from person to person via respiratory droplets and secretions. In *in vitro* studies demonstrate that SARS-CoV-2 infects human tissues by binding of the Spike glycoprotein to the angiotensin-converting enzyme type 2 (ACE2) receptor (Fig. 1). The ACE2 receptor is highly expressed in the vascular endothelium and tissues of the lung, heart, kidney, and small intestine. ACE2 is also expressed to a greater extent in cholangiocytes versus hepatocytes.²

COVID-19 has variable clinical manifestations ranging from asymptomatic acute infection to a mild-to-moderate flu-like illness. However, a substantial minority (5%-10%) of patients go on to acquire severe infection with systemic symptoms of myalgias, pneumonia, and weakness. Hospitalized subjects with SARS-CoV-2 are considered to have mild-to-moderate disease, whereas those

---

**Abbreviations:** ACE-2, angiotensin-converting enzyme type 2; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; AZT, azithromycin; COVID-19, coronavirus infectious disease 2019; CQ, chloroquine; CRP, C-reactive protein; DDI, drug-drug interaction; FDA, US Food and Drug Administration; GFR, glomerular filtration rate; HBV, hepatitis B virus; HCQ, hydroxychloroquine; ICU, intensive care unit; IL-6, interleukin-6; IV, intravenous; LOS, length of stay; NIH, National Institutes of Health; NSAID, nonsteroidal anti-inflammatory drug; RCT, randomized controlled trial; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; SC, subcutaneous; ULN, upper limit of normal.

From the Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, MI.

Potential conflict of interest: R.J.F. consults for Sanofi and received grants from Gilead, BMS, and AbbVie.

Received May 3, 2020; accepted May 8, 2020.

View this article online at wileyonlinelibrary.com

© 2020 by the American Association for the Study of Liver Diseases
who require supplemental oxygen, pressors, or intensive care unit (ICU) care are considered to have severe disease. Progression to acute respiratory distress syndrome (ARDS) is believed to be mediated, in part, by an overly exuberant host immune response (i.e., high serum ferritin, C-reactive protein [CRP], interleukin-6 [IL-6] levels) and may also be exacerbated by endothelitis from viral infection of the vascular endothelium.

Elevated serum aminotransferase levels are noted in 20% to 40% of patients with SARS-CoV-2 and are associated with increased mortality. In addition, patients with preexisting liver disease, particularly cirrhosis, have a higher rate of hospitalization and mortality when compared with comorbidity-matched control subjects. However, clinical jaundice is uncommon and is believed to be caused by cholestasis of sepsis in ICU patients rather than direct effects of the virus or by idiosyncratic drug toxicity in most cases.

**ANTIVIRALS**

Ongoing studies are attempting to prevent primary infection in health care workers and other individuals at high risk, as well as treat hospitalized patients with moderate-to-severe COVID-19 (Table 1). Study designs include randomized controlled trials (RCTs) and adaptive designs with varying primary endpoints that include infection rates, time to illness recovery, length of stay...
| Agent (Route/Mechanism) | Target Population (Study Endpoint) | Efficacy Data | Safety Issues |
|-------------------------|------------------------------------|---------------|---------------|
| **Antiviral agents**    |                                    |               |               |
| Remdesivir (IV/nucleotide analogue) | Mild to severe (time to improvement) | *In vitro* and animal models | Well tolerated in Ebola |
|                         |                                     | Cohort study showed clinical improvement and reduced mortality | Few DDIs anticipated |
|                         |                                     | NIH RCT: 31% faster recovery, reduced mortality | 20%-30% reversible AST/ALT elevations |
|                         |                                     | China RCT: no benefit | Nausea/vomiting, rash |
|                         |                                     | Emergency Use Authorization granted by FDA as additional studies are awaited | Contraindicated: |
|                         |                                     |                           | GFR < 30 mL/min |
|                         |                                     |                           | AST/ALT > 5× ULN |
|                         |                                     |                           | Hypoalbuminemia |
| Remdesivir (IV/nucleotide analogue) | Mild to severe (hospital LOS) (symptom duration) | Three RCTs with mixed results regarding clinical improvement, radiological findings, and viral clearance | QT prolongation (↑ with AZT) |
|                         |                                     | Largest RCT (n = 150): improved CRP/neutropenia, higher adverse events in HCQ arm, no difference in viral clearance by PCR | Safer than CQ |
|                         |                                     | NIH and FDA recommend only in carefully monitored setting | Contraindicated: |
|                         |                                     |                           | QT > 500 ms |
|                         |                                     |                           | Cardiomyopathy |
|                         |                                     |                           | Glucose-6-phosphate dehydrogenase deficiency |
|                         |                                     |                           | Pregnancy/breast-feeding |
| HCQ (+/− AZT) (oral/host proteins) | Mild to severe (hospital LOS) (symptom duration) | RCT (n = 81) of high-versus low-dose CQ: stopped early due to higher mortality in high-dose CQ group (all received AZT); no difference in viral clearance | Higher risk for QT prolongation, DDIs, toxicities |
|                         |                                     | Weaker *in vitro* effects versus HCQ | Same as above |
| **Immunomodulators**    |                                    |               |               |
| Tocilizumab (IV/monoclonal IL-6 receptor antagonist) | Severe respiratory failure +/- ↑ IL-6 (% requiring mechanical ventilation/FiO2/ mortality) (pulmonary function) | RCT ongoing | Single versus repeated dosing |
|                         |                                     | One uncontrolled study (n = 21) showed clinical improvement and reduced LOS | Opportunistic infections |
| Sarilumab (Kevzara) (SC/monoclonal anti-IL-6 antibody) | Preliminary data showed no benefit versus placebo | RCT ongoing | HBV reactivation |
| Siltuximab (IV/monoclonal anti-IL-6 antibody) | Data from salvage therapy in SARS/MERS showed clinical improvement | RCT ongoing | 1%-5% cytopenias |
|                         |                                     | Chinese case series (n = 15) showed reduced mortality and no adverse events | 20%-40% AST/ALT elevation |
|                         |                                     | Transfusion reactions (transfusion-related acute lung injury, anaphylaxis) | Contraindicated: |
|                         |                                     | Donor-related infections | Absolute neutrophil count < 2,000 |
|                         |                                     | Hypervolemia | Platelets < 100,000 |
|                         |                                     | Impaired host antibody response | ALT > 5x ULN |
| **Convalescent plasma (IV)** | Severe respiratory failure (safety, feasibility, mortality, clinical improvement) | Data from salvage therapy in SARS/MERS showed clinical improvement | Transfusion reactions (transfusion-related acute lung injury, anaphylaxis) |
|                         |                                     | Chinese case series (n = 15) showed reduced mortality and no adverse events | Donor-related infections |
|                         |                                     | Hypervolemia | Impaired host antibody response |
Potential Treatments for SARS-CoV-2 Infection  
Berry and Fontana

LOS), and mortality. Serial quantitative SARS-CoV-2 RNA levels from secretions may prove to be a useful prognostic and/or efficacy biomarker, but further studies using standardized preprocedural sample acquisition and analytical methods are needed.

Remdesivir
Remdesivir is an intravenously (IV) administered nucleotide analogue with broad activity against many RNA viruses. In vitro and animal studies have demonstrated potent antiviral efficacy against SARS-CoV-2 as a chain terminator (Fig. 1). The drug is typically given as a loading dose followed by 7 to 10 days of daily infusions. Remdesivir is largely eliminated by the kidney and contraindicated if glomerular filtration rate (GFR) is < 30 mL/min due to potential vehicle accumulation.5

A compassionate use study of remdesivir demonstrated that 36 of 53 inpatients (68%) had an objective improvement in their oxygenation status, and 57% of the intubated patients were successfully extubated during a median follow-up of 18 days.5 The most common adverse events were serum aminotransferase elevations (23%), diarrhea (9%), and rash (4%). Currently, the National Institutes of Health (NIH) is conducting an adaptive, double-blind RCT of remdesivir versus placebo for 10 days in 1037 patients with a primary efficacy endpoint of time to recovery defined as hospital discharge or no longer requiring supplemental oxygen. Preliminary interim results show that patients who received remdesivir had a 31% faster recovery time than placebo (11 versus 16 days; \( P < 0.001 \)) and a potential mortality benefit (8% versus 11.6%; \( P = 0.059 \)). However, another study of 237 Chinese patients demonstrated no improvement in time to recovery (21 versus 23 days) or 28-day mortality (14% versus 13%).7 Furthermore, the rate of viral load decline was similar in both groups, but the incidence rate of aminotransferase elevations was numerically lower in the remdesivir group (5% versus 12%). An ongoing open-label RCT of various remdesivir dosing regimens in 6000 patients with severe disease is eagerly awaited.8

Hydroxychloroquine/Chloroquine
Hydroxychloroquine (HCQ) is an orally administered antimalaria drug with immunomodulatory properties that has a better safety profile than chloroquine (CQ). Based on in vitro studies, HCQ may interfere with endosomal uptake and processing of SARS-CoV-2 (Fig. 1). Three small RCTs involving 30, 62, and 22 patients had mixed results with regard to viral clearance and clinical and/or radiological improvements.9 Since then, another open-label RCT of 150 Chinese patients with mild-to-moderate disease that used higher doses of HCQ demonstrated no difference in viral clearance or improvement in CRP, but adverse events were more common in the HCQ arm (30% versus 9%).10 Other studies are exploring HCQ/CQ with azithromycin (AZT), but there are increasing reports of potential cardiac toxicity, including QT prolongation.11,12 It is currently recommended that this combination of drugs not be administered outside of a carefully monitored clinical trial setting.13

OTHER ANTIVIRAL AGENTS
Other approved drugs being tested include favipiravir and umifenovir with efficacy in influenzae; nitazoxanide, which is approved for cryptosporidium; and camostat, which is used for pancreatitis in Japan.1 The human immunodeficiency virus protease inhibitor, lopinavir-ritonavir, had no demonstrable efficacy in a large RCT and is currently not recommended.14

IMMUNOMODULATORS
The pathophysiology of severe disease and multiorgan failure in COVID-19 is believed to result from a dysregulated immune response, or cytokine storm. Numerous immunomodulators are under investigation for patients with severe, life-threatening disease, but available data indicate no demonstrable benefit from corticosteroids.15 As a result, initiation of high-dose corticosteroids is not recommended for hospitalized patients with COVID-19 without ARDS.15

IL-6 Blockade
Tocilizumab, sarilumab, and siltuximab are parenterally administered monoclonal antibodies that target the IL-6 signaling pathway. Uncontrolled data with these agents have shown promising results with rapid clinical improvement and decreased LOS.16 However, a preliminary report showed no benefit in an RCT of sarilumab versus placebo.17 Known side effects of these agents include an increased risk for opportunistic infection, hepatitis B virus (HBV) reactivation, cytopenias, and elevated aminotransferase levels in 20% to 40% of treated patients, including rare instances of acute liver failure.
Potential Treatments for SARS-CoV-2 Infection  

Berry and Fontana

Convalescent Plasma

Antibodies from patients who have recovered from COVID-19 may help improve free viral clearance and infected host cell clearance (Fig. 1). Convalescent plasma was used as salvage therapy in other coronavirus outbreaks, including SARS and Middle East Respiratory Syndrome (MERS), with a reduction in mortality and minimal adverse events in observational studies. Small case series demonstrate reduced mortality in patients with COVID-19, but the optimal donor, volume, and frequency of plasma administration are unknown. In addition, vaccines derived from the SARS-CoV-2 spike glycoprotein and/or nucleoproteins are under development to prevent primary infection, but these studies will likely take 12 months or more to complete.

CONCOMITANT MEDICATIONS

Chronic nonsteroidal anti-inflammatory drug (NSAID) use can lead to up-regulation of ACE2 receptors, which has raised concerns regarding more severe SARS-CoV-2 infection (Table 2). Although there is no causal evidence showing adverse outcomes in patients with COVID-19 receiving NSAIDs, the World Health Organization and FDA do not recommend for or against the use of NSAIDs until further studies are completed. Acetaminophen is an effective analgesic that can be safely used in patients with COVID-19 as long as the total dose does not exceed 2 to 3 g/day.

ACE Inhibitors

These antihypertensive medications are used by many older adults with underlying hypertension and diabetes mellitus who are at greater risk for adverse outcomes with COVID-19. There are mixed reports whether these drugs may increase the expression of the ACE2 receptor or whether angiotensin receptor blockers (ARBs) may block viral entry. Current recommendations are to continue these drugs in patients with a medical indication while therapeutic clinical trials of ARBs are being undertaken.

TABLE 2. COMMONLY USED MEDICATIONS IN PATIENTS WITH SARS-COV-2 INFECTION

| Concomitant Drug | Safety Issues |
|------------------|--------------|
| Acetaminophen    | Preferred analgesic for fevers and myalgias 2 to 3 grams maximal dose per day |
| NSAID            | ACE2 receptor upregulation, Concern for new onset or worsening kidney injury |
| ACE inhibitor/ARB| Theoretically may block viral entry, Recommend continuation in patients with diabetes or hypertension, No role of this time to start for antiviral effects, Many patients have elevated D-dimer levels and may be hypercoagulable with endothelitis, SQ Heparin for deep vein thrombosis prophylaxis is recommended for hospitalized patients, Role of therapeutic anticoagulation not established |
| Heparin          | SQ Heparin for deep vein thrombosis prophylaxis is recommended for hospitalized patients, Role of therapeutic anticoagulation not established |

SUMMARY

A number of promising antiviral, immunomodulatory, and biological approaches are being tested in patients with SARS-CoV-2 infection. Individuals with pre-existing liver disease and transplant recipients appear to be at increased risk for poor outcomes. Mild serum aminotransferase elevations are frequently seen in hospitalized patients and are associated with poorer outcomes. The completion of ongoing studies to improve the diagnosis, prognosis, and treatment of afflicted patients, as well as primary prevention studies using novel vaccines, is eagerly awaited.

CORRESPONDENCE

Robert J. Fontana, M.D., Division of Gastroenterology and Hepatology, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109. E-mail: rfontana@med.umich.edu

REFERENCES

1) Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. Available at: https://doi.org/10.1001/jama.2020.6019
2) Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-430.
3) Sultan S, Altayar O, Siddique SM, et al. Institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. Available at: https://doi.org/10.1053/j.gastro.2020.05.001
4) Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 amongst patients with pre-existing liver disease in the United States: a multi-center Research Network Study. Clin Gastro Hepatol. Available at: https://doi.org/10.1053/j.gastro.2020.04.064
5) Mulangui S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-2303.
6) Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. Available at: https://doi.org/10.1056/NEJMoa2007016
7) Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. Available at: https://doi.org/10.1016/S0140-6736(20)310
8) ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). Available at: https://clinicaltrials.gov/ct2/show/NCT04292899?term=remdesivir&cntry=US&draw=2&rank=2. Accessed April 30, 2020.

9) Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. Available at: https://doi.org/10.1016/j.jclinepi.2020.04.016

10) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. Available at: https://doi.org/10.1101/2020.04.02.20047050

11) Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Available at: https://doi.org/10.1016/j.ijantimicag.2020.105949

12) Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv. Available at: https://doi.org/10.1101/2020.04.02.20047050

13) US Food and Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Published April 24, 2020. Accessed April 30, 2020.

14) Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-1799.

15) Infectious Diseases Society of America. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated April 21, 2020. Accessed April 30, 2020.

16) Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. Available at: https://doi.org/10.1073/pnas.2005615117

17) Regeneron Pharmaceuticals Inc. Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients. Available at: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive. Published April 27, 2020. Accessed April 30, 2020.

18) Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398-400.

19) Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-1589.

20) Mehra MR, Desai SS, Kuy W, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. Available at: https://doi.org/10.1056/NEJMoa2007621